Compare Natera Inc. Common Stock (NTRA) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs SOLAI Limited — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: Natera Inc. Common Stock is far larger — about 64.8× SOLAI Limited's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and SOLAI Limited for 42 Days on average.
| NTRA | SLAI | |
|---|---|---|
Market Cap | $57.03B | $880.09M |
Volume | 1,131,157 | 122,720 |
Sector | Health | Technology |
52-Week High | $425.64 | $21.63 |
52-Week Low | $179.42 | $2.74 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $56.18B | $879.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SOLAI Limited (SLAI) trades at $3.72 with no recent price movement, showing a mixed technical picture despite a bullish signal from indicators. The company faces severe financial distress with negative gross and net income margins, though it recently beat Q2 2025 EPS expectations. Recent developments include an extraordinary general meeting and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial execution and regulatory risks. While technical indicators suggest potential upside, fundamental weaknesses and delisting proceedings present clear downside risks. Investors should approach with caution given the company's negative profitability and ongoing corporate challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
